Celia Brown
Woodland Hills, CANPI 1740454669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Galderma Laboratories, L.p. at 35.5% of the total.
Across 40 payments — averaging $33.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$476
- Phathom Pharmaceuticals, Inc.$391
- AbbVie$350
- Amgen$122
Across 95 payments — averaging $19,040 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$780K
- Biohaven Pharmaceutical Holding Company Ltd.$340K
- Biohaven Pharmaceuticals, Inc.$298K
- Biogen$232K
- Eli Lilly$110K
- Amgen$49K
What the payments were for
- Food & beverage$1,338100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 16 | $476 |
| Phathom Pharmaceuticals, Inc. | 3 | $391 |
| AbbVie(2 entities) | 20 | $350 |
| Amgen | 1 | $122 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sumatriptan Succinate | 11 | $126 |
| Zolpidem Tartrate | 11 | $76 |
| Levothyroxine Sodium | 12 | $43 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.